Australian company Actinogen Medical has announced that results from its Phase 2 proof-of-concept trial of XANAMEM (emestedastat) have been published in the British Journal of Psychiatry, reporting meaningful antidepressant activity in a population described as difficult to treat. …
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News